← Trials/Trial dossier/NCT00242632

CompletedPhase NAResults posted

Treatment With Namenda in Women at Risk for Cognitive Decline

Cognitive Effects of Memantine in Postmenopausal Women at Risk of Dementia: a Pilot Study

Lead sponsor

Stanford University

Asset

Memantine

Listed sites

Recruiting sites

Enrollment

actual

Study population

MCI / preclinical Alzheimer’s

Key I/E criterion

•Family history of Alzheimer’s disease required

Primary endpoint

•California Verbal Learning Test - Second Edition Proactive Interference Test

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID95239

NCT IDNCT00242632

Timeline

Milestones

Study start2004-06 (month precision)

Study first posted2005-10-20estimated

Primary completion2009-12actual (month precision)

Study completion2009-12actual (month precision)

Results first posted2017-05-17actual

Last update posted2017-06-14actual

Assets

Drug assets

Memantine

Study populations

Who this study enrolls

MCI / preclinical Alzheimer’s

Eligibility

Who can enroll

Minimum age50 Years

Maximum age65 Years

SexFemale

Healthy volunteersAccepted

Inclusion criteria

•Women between the ages of 50-65

•Willing to sign Human Subjects Protection Consent Form

•Personal or family history of mood disorder

•Hypothyroidism

•Diabetes

•Family history of Alzheimer's disease

Exclusion criteria

Possible or probable Alzheimer's disease or dementia

•History of cerebrovascular disease

•History of myocardial infarction within the previous year

•History of unstable heart disease

•Uncontrolled hypertension

•Less than 8 years of education

•English as a 2nd language

•Uncorrected vision or hearing deficits

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Memory

Executive function / language

Memory

2 endpoints

Primary/protocol endpoint

Change in California Verbal Learning Test - Second Edition Proactive Interference Test Between Time 1 and Time 2

Time frame:6 months

change from baseline, improvement

Primary/registry result

Change in California Verbal Learning Test - Second Edition Proactive Interference Test Between Time 1 and Time 2

Time frame:6 months

change from baseline, improvement

Posted result

Group	Value (mean), percentage of target words recalled	Standard deviation
T1-T2n=22 Participants	20.41	5.63

Executive function / language

2 endpoints

Secondary/protocol endpoint

Change in Delis-Kaplan Executive Function System (DKEFS) Verbal Fluency Category Switching Between Time 1 and Time 2

Time frame:6 months

change from baseline, improvement

Secondary/registry result

Change in Delis-Kaplan Executive Function System (DKEFS) Verbal Fluency Category Switching Between Time 1 and Time 2

Time frame:6 months

change from baseline, improvement

Posted result

Group	Value (mean), correct words	Standard deviation
T1-T2n=22 Participants	1.11	0.23

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.